What drove AYA.AX stock price today?

AYA.AX stock closed at **A$3.23** on 23 Feb 2026. Trading was driven by modest volume and positioning ahead of Artrya’s earnings announcement on 24 Feb 2026 and continued attention on Salix AI commercial progress.

How does Meyka AI view AYA.AX stock?

Meyka AI rates AYA.AX **63.36/100 (Grade B, HOLD)**. The score balances AI growth potential with weak current earnings and elevated valuation. This grade is informational and not investment advice.

What are realistic price targets for AYA.AX stock?

Scenario targets: a conservative target of **A$4.50** (≈**+39.32%**) and a bull target of **A$8.00** (≈**+147.68%**). These assume successful clinical adoption and commercial scale; results are not guaranteed.

What are the main risks for AYA.AX stock?

Key risks for AYA.AX stock include continued negative EPS (**-A$0.18**), heavy R&D burn, high PB ratio (**15.97**), and slow hospital procurement. Regulatory or clinical setbacks would pressure the share price.

AU Stocks

AYA.AX Artrya Limited (ASX) 23 Feb 2026: A$3.23 close, AI growth outlook

ByHuzaifa Zahoor February 23, 2026February 23, 2026

AYA.AX stock closed at A$3.23 on 23 Feb 2026 after trading between A$3.16 and A$3.32. Investors are watching Artrya Limited (AYA.AX, ASX) because its Salix AI product targets coronary artery disease detection. Near-term trading shows mixed momentum but long-term AI adoption could lift revenue if clinical and commercial rollouts scale. This piece breaks down valuation, technicals, Meyka AI grading, and forecast scenarios to help investors assess risk and reward on the ASX in AUD.